Bank Julius Baer & Co. Ltd, Zurich Halozyme Therapeutics, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 15, 2022	SELL	$31.82 - $40.75 $31,820 - $40,750	-1,000 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$38.47 - $46.42 $346 - $417	9 Added 0.91%	1,000 $41,000
Q2 2021 Jul 23, 2021	SELL	$38.84 - $51.31 $349 - $461	-9 Reduced 0.9%	991 $45,000
Q1 2021 May 10, 2021	SELL	$39.51 - $51.45 $276 - $360	-7 Reduced 0.7%	1,000 $42,000
Q4 2020 Feb 24, 2021	BUY	$25.81 - $43.62 $14,350 - $24,252	556 Added 123.28%	1,007 $43,000
Q4 2020 Feb 12, 2021	SELL	$25.81 - $43.62 $19,331 - $32,671	-749 Reduced 62.42%	451 $43,000
Q2 2020 Aug 12, 2020	BUY	$16.25 - $26.81 $19,500 - $32,172	1,200 New	1,200 $32,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.